1[2]Bhattacharya S.Uncertain advances:a review of the final phases of the smallpox eradication program in india,1960-1980.Am J Public Health,2004,94(11):1875-1883.
2[3]Kretzschmar M,Wallinga J,Teunis P,et al.Frequency of adverse events after vaccination with different vaccinia strains[J/OL].PLoS Med,2006,3(8):e272[2007-01-16].http://medicine.plosjournals.org/perlserv/?request=set-document&doi=10.1371/journal.pmed.0030272.
3[4]Qutaishat SS,Olson JL.Bioterrorism preparedness:the smallpox vaccine debate.Clin Med Res,2003,1(2):85-86.
4[5]World Health Organization.Recommendations for the production and quality control of smallpox vaccine,revised 2003//World Health Organization.WHO Technical Report Series,No.926,2004[M/OL].Geneva:WHO,2004:Annex 1 27-64[2007-07-16].http://www.who.int/biologicals/publications/trs/areas/vaccines/smallpox/Annex%201%20(27-64)TRS926Smallpox2003.pdf.
5[6]McCurdy LH,Rutigliano JA,Johnson TR,et al.Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.J Virol,2004,78(22):12471-12479.
6[9]China Pharmacopoeia Committee.Pharmacopoeia of the People's Republic of China:Volume 2,2005.Beijing:Chemical Industry Press,2005:Appendix 172-173.(in Chinese)
7Fowler V L,Paton D J,Rieder E,et al.Chimeric foot-and-mouth disease viruses;evaluation of their efficacy as potential marker vaccines in cattle[J].Vaccine,2008,26(16):1 982-1 989.
8Van Rensburg H G,Mason P W.Construction and evaluation of a recombinant foot-and-mouth disease virus:implications for inactivated vaccine production[J].Ann NY Acad Sci,2002,969:83-87.
9Bertoletti A,Gehring A.Therapeutic vaccination and novel strategies to treat chronic HBV infection[J].Expert Rev Gastroenterol Hepatol,2009,3 (5):561-569.
10Chen W,Liu M,Jiao Y,et al.Adenovirus-mediated RNA interference against foot-and-mouth disease virus infection both in vitro and in vivo[J].Virol,2006,80(7):3 559-3 556.
